Aims: Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a high-grade, aggressive tubulopapillary carcinoma, arising predominantly in the setting of the hereditary leiomyomatosis-RCC syndrome of familial uterocutaneous leiomyomatosis and deficiency of FH. In contrast, succinate dehydrogenase (SDH)-deficient RCC is a lower-grade oncocytic carcinoma with cytoplasmic flocculence/vacuolation and inclusions, arising mostly in individuals harbouring germline mutations of subunit B of the SDH complex (SDHB). Herein we aim to report the clinicopathologic features of a novel form of FH-deficient RCC showing a low grade oncocytic morphology, reminiscent of SDH-deficient RCC. Methods and results: These distinctive, low-grade oncocytic neoplasms, with solid, nested and focally tubular architecture (2-90 mm), arose in four males (aged 11-41 years). Uniform cytology of polygonal cells, with flocculent, vacuolated eosinophilic cytoplasm with scattered inclusions, fine chromatin, and inconspicuous nucleoli, was apparent. Despite these features suggestive of SDH-deficient RCC, each tumour was confirmed as an FH-deficient carcinoma with retained SDHB expression. One case showed a synchronous, anatomically separate, typical highgrade FH-deficient RCC; one other showed such a tumour at nephrectomy 4 years later. No progression has been noted at 3 and 7 years in the cases with only the SDH-like lesions; the two cases with separate, typical FH-deficient RCCs progressed. Conclusions: In summary, we characterize a novel oncocytic type of FH-deficient RCC with a striking
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Introduction
Recent series 1, 2 have shed much light on the clinicopathological features of succinate dehydrogenase (SDH)-deficient renal cell carcinoma (RCC). 3, 4 Proceeding from the initial observation of kidney tumours in kindreds with germline SDHB mutations and a predisposition to develop epithelioid gastrointestinal stromal tumours and multiple pheochromocytomas and paragangliomas, 5 greater experience suggests that these RCCs are morphologically distinctive, 4 are under-recognized but rare, arise with a slight male predominance in middle-aged adults, and are frequently bilateral.
1,2 The morphology is quite characteristic, with tumours composed of small nests and sheets of oncocytic polygonal cells, unencapsulated, and sometimes entrapping peripheral benign tubules. Cytologically, they show vacuolated pink cytoplasm and variably prominent, pale eosinophilic inclusions, thought to represent dysfunctional mitochondria. 6 The nuclear features are usually low-grade and monotonous, with what we have called a neuroendocrinelike chromatin pattern. 2 A subset of cases, however, have shown sarcomatoid transformation with overt nuclear atypia and an aggressive course. Although most SDH-deficient RCCs that have been tested have been shown to harbour SDHB mutations, scattered reports have identified SDHA and SDHC mutations as well. [7] [8] [9] In any case, to assist in their recognition, SDHB immunohistochemistry (IHC) has been used for the detection of tumours with SDH subunit mutations based on consistent loss of SDHB expression by IHC, whether there is SDHA, SDHB, SDHC or SDHD mutation, owing to mitochondrial complex II instability. 3 In contrast, hereditary leiomyomatosis-RCC (HLRCC) syndrome represents another RCC syndrome, related to germline mutation of the fumarate hydratase (FH) gene, consisting of highly penetrant cutaneous (>90% of males and females) and uterine (~70% of females) leiomyomatosis with less prevalent (10-30%) [10] [11] [12] 'type 2 papillary' RCC 13 arising in both males and females over a diverse age range. Adrenocortical adenomas have been reported in~10% of affected subjects. 14 The RCCs arising in HLRCC show a much more variable, high-grade morphology, including papillary, tubulopapillary, cribriform, cystic and infiltrative collecting-duct like patterns. 15, 16 Prospective recognition of these tumours is emphasized, owing to their remarkable aggression, for which IHC for FH (lost in most cases with mutations 17 ) and for aberrant succination of nuclear and cytoplasmic proteins [2-succinylcysteine (2SC 16 )] has been used. Although most cases are thought to occur with germline rather than somatic FH mutations, 18 recent data have identified apparently somatic mutations in sporadic uterine leiomyomas 19 and even high-grade papillary RCCs. 20 In any case, a great many cases showing FH deficiency by IHC do not show signs of this syndrome. For this reason, we have recently proposed 21 a term, 'FH-deficient RCC', for provisional use, with recommendation of genetic consultation, in morphologically and immunohistochemically suggestive cases without apparent syndromic features and unavailable genotyping. 17, 22 In a recent interinstitutional review of FH-deficient RCCs, 22 we noted several morphological outliers. On the basis of prior experience with SDH-deficient RCC, 2 we noted tumours with low-grade oncocytic morphology, suggestive of SDH deficiency, among cases with clinical, morphological, immunohistochemical or molecular evidence suggestive of FH deficiency. Careful review of published cases of HLRCC identified another case with such morphology, 23 which we also reviewed. Intrigued by the morphological overlap of these carcinomas across syndromes defined by disparate classic phenotypes but shared metabolic alterations, we present the findings herein.
Marerials and methods
In accordance with the ethical principles of the Declaration of Helsinki, under Institutional Review Board (IRB)-approved protocols (VCU IRB no. HM20002545, valid to 26 April 2017; CSMC IRB no. Pro00027348; valid to 31 January 2018), granting waivers of consent, cases of RCC arising in the setting of known or suspected HLRCC were identified retrospectively from the files of the authors. All sections of every case were obtained and reviewed, and deidentified clinicopathological data were collected. One case has been reported previously by Alrashdi et al., 23 and this was also re-reviewed with extended follow-up. Routine IHC, with protocols and evaluation as reported previously for FH 22 and 2SC, 16 and SDHB and SDHA, 2 was employed. For one case, multiplexed polymerase chain reaction-based next-generation sequencing (NGS) of tumour genomic DNA was performed with the Ion Ampliseq Comprehensive Cancer Panel targeting 409 cancer-related genes, including FH (and SDHB), with a validation and analysis pipeline, and copy number alteration detection as previously reported, [24] [25] [26] with cutoffs for variant detection exactly as previously reported. 22 Table 1 showed separate (one anatomically distant from the oncocytic tumour; one presenting 4 years later at completion nephrectomy) high-grade FH-deficient RCCs. Two cases provided strong evidence of HLRCC, including concurrent multiple cutaneous leiomyomata (Case 1), and germline mutation-confirmed HLRCC (Case 2). Case 3 also had a suggestive history, including a personal history of a first-degree relative having succumbed to metastatic RCC, and a personal history of 'multicystic kidneys' by imaging. No data are available regarding HLRCC-associated signs for Case 4. In terms of clinical outcome, the two cases with only low-grade oncocytic carcinomas are free of disease at nearly 3 years and >7 years post-nephrectomy. The two cases with separate high-grade tumours showed progression, at presentation in Case 3 (liver metastasis showing morphology of the highgrade tumour at frozen section) and at 3 months after completion nephrectomy (although after 4 years had elapsed without progression since the partial nephrectomy with the oncocytic RCC) in Case 4.
Results

C L I N I C O P A T H O L O G I C A L F E A T U R E S
The specimens evaluated were three radical nephrectomies and one partial nephrectomy. The nephrectomy of Case 1 harboured an ipsilateral adrenocortical adenoma (27 mm) ( Figure 1B ), whereas cutaneous biopsies performed concurrently with nephrectomy for suspected metastasis (Figure 1C) proved to be cutaneous, pilar-type leiomyomatosis ( Figure 1D ). The tumours were described as yellow or tan (Figure 2A ), and measured, on gross examination, from 2 mm up to 90 mm. In three cases, these were seen adjacent to variable background cystic change ( Figures 3A, 4A ,C, and 5A). In each case, the tumours were grossly unencapsulated but appeared not to have infiltrated the adjacent structures, bulging but confined to the kidney.
H I S T O L O G I C A L F E A T U R E S
Morphologically, these tumours showed low-grade oncocytic morphology, with confluent solid or nested confluent growth and prominent nodularity, closely juxtaposed to the adjacent renal parenchyma (Figures 2B and 3A) . At higher power, the architecture showed a mixed pattern, in some areas with tubular morphology (Figures 2C,D and 3B,C), sometimes dilated to impart a microcystic appearance with pink luminal contents ( Figure 2C ). One nodule showed prominent stromal oedema with dispersed tubular aggregates of cells ( Figure 2D) ; in other foci, tubular growth was more packed (inset). Cytologically, consistent oncocytic features were seen, with tumours being composed of polygonal cells with eosinophilic cytoplasm with scattered vacuoles and predominantly round, regular nuclei ( Figures 2E, 3C , 4B,D, and 5B). The chromatin was finely granular; many examples showed micronucleoli that were not prominent at 910 [International Society of Urological Pathology (ISUP) grade 2]. Numerous stromal mast cells were apparent in many areas ( Figure 2E ). All cases showed variable cytoplasmic flocculence or vacuolation; in three cases (Cases 2-4), cytoplasmic inclusions of pink hyaline material reminiscent of those that have been described in SDH-deficient RCC were readily identifiable ( Figures 3C and 5B) . No coagulative tumour cell necrosis was identified in any of these tumours, and nor were features of vascular invasion present, including in the multifocal cases, which were interpreted histologically as independent neoplastic foci.
Two cases (Cases 3 and 4) showed separate RCCs with features that have been associated with typical high-grade FH-deficient RCC. Case 3 showed a 35-mm tumour, in the upper pole of the kidney, distant from the oncocytic tumours, with prominent tubulocystic morphology and poorly differentiated, solid areas with a cribriform and syncytial appearance ( Figure 4E,F) ; a metastatic liver lesion with this morphology was present at nephrectomy. In Case 4, a completion nephrectomy was performed 4 years after the partial nephrectomy (which had shown the low-grade oncocytic RCC), and a 50-mm high-grade RCC with tubulocystic and infiltrative collecting-duct carcinoma-like areas was identified, invasive of renal sinus adipose ( Figure 5C ). In both of these cases the cytology of the high-grade tumours was high-grade (ISUP grade 3-4), with a syncytial appearance and prominent, viral inclusion-like nucleoli with perinuclear halos ( Figure 5D ).
In all four cases, the oncocytic tumours showed strong/diffuse retained expression of both SDHB and SDHA, with loss of expression of FH and induction of strong nucleocytoplasmic 2SC positivity ( Figures 2F,  3D, and 5B). PAX8 expression was diffuse in all of the oncocytic tumours (not pictured), with variable, patchy expression of pancytokeratin AE1/AE3 and the oncocytic renal neoplasia-associated marker kidney-specific cadherin (Ksp-cadherin), as shown in Table 2 . It is of note that the cutaneous leiomyoma seen in Case 1 also showed SDHB/SDHA positivity with loss of FH ( Figure 1D ), whereas the separate high-grade carcinomas seen in Cases 3 and 4 were both FH-deficient. In Case 3, NGS was performed on the low-grade oncocytic RCC, and identified homozygous FH frameshift mutations (p.K80 fs). This mutation was identical to the homozygous FH mutations observed in the anatomically separate high-grade FH-deficient RCC. 22 Nevertheless, on comparison of genome-wide copy number alterations between these two separate carcinomas, the oncocytic tumour lacked the copy number gains (chromosome 8q) and losses (chromosome 18) seen in the high-grade FHdeficient carcinoma ( Figure 4H ). Consistent with the IHC findings, no SDHB mutations were identified.
Discussion
Recent years have seen the recognition of distinctive morphological features of subtypes of RCC associated with genetic syndromes, including the SDH-deficient RCCs associated with familial paraganglioma/ pheochromocytoma syndromes 3,4 and the FH-deficient RCCs associated with HLRCC syndrome. 15 From the standpoint of the diagnostic pathologist, recognition of these RCC subtypes is of the utmost importance, owing to the need to risk-stratify individual tumours on the basis of increasing published experience 1,2,17,22 and to recommend genetic counselling and testing for patients and their families.
With regard to the present cases, we first note that the evidence available suggests that three of these cases represent HLRCC, although proof of germline mutation of FH (observation of the same constitutional FH mutation in two separate generations) is unavailable except for the second case, which arose in a patient from a well-characterized HLRCC family. 23 The first case, arising in an individual showing multiple, histologically confirmed cutaneous leiomyomas, and the third case, with the separate 'type 2 papillary' RCC or 'collecting duct carcinoma' 27 before the age of 40 years and with an affected first-degree relative, would meet the criteria reported by Menko et al. 28 for likely HLRCC. Quite suggestive of a constitutional mutation, this third case also had the same homozygous FH mutation detected in the anatomically separate SDH deficientlike and typical high-grade FH-deficient RCCs. Notably, no data regarding a family history of HLRCC or a personal or family history of uterocutaneous leiomyomatosis are available for the fourth case. In light of recently reported data showing that uterine leiomyomata and even FH-mutant RCCs may occur through somatic mutations, 19, 20 we can only regard this case as an FH-deficient RCC. 21, 22 We acknowledge the wisdom of the opinion held by some that explicit observation of a germline FH mutation remains the true gold standard for HLRCC diagnosis; 15, 16 in three of our cases, this will remain impossible (not allowed under the retrospective protocols governing the study). Our inability to retrospectively perform genetic testing for constitutional changes in FH and SDHB remains the most important limitation of this study. Moreover, it underscores the essential role of the surgical pathologist in the early recommendation of genetic consultation for patients with tumours in this morphological and clinical spectrum. Only accumulated, carefully genetically documented clinical experience will answer the question of whether FH-deficient or SDH-deficient RCCs occur sporadically by somatic mutation at any frequency. Indeed, SDH-deficient paragangliomas 29, 30 and other lesions with only somatic SDH subunit mutations 31 have been described, making this issue all the more salient.
With regard to the oncocytic tumours, we do not argue that these tumours represent perfect morphological phenocopies of the most characteristic SDH-deficient RCCs. However, in each case, when encountered after our prior studies of SDH-deficient RCCs, 2 we were sufficiently suspicious that we ordered SDH-deficient workup (by IHC). Each case showed oncocytic morphology with stromal mast cells and areas of distinctive cytoplasmic flocculence and vacuolation, with at least focal inclusion-like formations. The predominant architectural pattern was solid or nested, although a tubular or pseudoglandular pattern, as reported previously in SDH-deficient RCCs, 1 was prominent in areas of two of the cases. Pancytokeratin AE1/AE3 was positive in a variable, patchy manner; Ksp-cadherin was positive in three cases, similarly to SDH-deficient RCC, 2 as is characteristic of oncocytic renal neoplasia generally, 32 as was PAX8. Most important, however, was the observation in all three tumours of consistently retained SDHB expression in a strong, diffuse manner, reflective of an intact SDH complex. 33 In contrast, FH expression was lost and 2SC expression was strongly, diffusely induced in a nucleocytoplasmic manner, a pattern that has proven, in our experience 16, 22, 34 and that of others, 17, 35, 36 to be demonstrative of FH mutation and loss of function. Thus, we interpret the FH-negative/ 2SC-positive immunophenotype in each of these tumours as being confirmatory of their specificity to FH deficiency and exclusive of their representing an aetiologically unrelated epiphenomenon (sporadic-type carcinomas arising in the polycystic background, for instance). In summary, we describe four intriguing cases: tumours with low-grade oncocytic morphology and variable cytoplasmic vacuolation and flocculence. On morphological grounds, these tumours were first deemed to be quite reminiscent of SDH-deficient RCC. However, immunophenotypic workup points to their representing a novel morphological type of FH-deficient carcinoma, including loss of FH expression, induction of strong, diffuse nucleocytoplasmic 2SC immunostaining, and retained expression of SDHB, to say nothing of the clinical features that are quite suggestive of (or confirmed) HLRCC in three of them. We speculate that these tumours represent yet another example of an emerging phenomenon of phenotypic 'crossover lesions' between FH-deficient and SDH-deficient syndromes, analogous to recently described paragangliomas occurring in the setting of germline FH mutation. 35, 37, 38 Two of these novel cases also raise the possibility that, when not associated with a high-grade FH-deficient RCC, this oncocytic tumour type could be associated with a more favourable outcome. High-grade FH-deficient RCCs have been associated with progression and/or death from disease in 30-80% of cases. 15, 17, 22 Our experience with these low-grade oncocytic tumours emphasizes the importance of morphological context for interpreting IHC and molecular findings. Despite the shared 'FH-deficient RCC' status of both the low-grade oncocytic tumours and typical high-grade FH-deficient RCCs, such a high-risk label would have been inappropriate for the low-grade tumours, given that progression was only seen in cases with a separate high-grade tumour. Certainly, much more study is needed, and, prospectively, we recommend careful inquiry regarding the nature of any syndromal signs and the use of SDHB, SDHA and FH IHC, as well as genetics referral, for concerning cases. Moreover, given the presence of anatomically (or chronologically) separate, disparate lesions of very different grades, we recommend careful correlation between imaging, sampling and histopathology for surveillance or sampling protocols.
